137 / 208
PEPaNIC trial
135
7
Kidney Failure with renal-replacement therapy - no. (%)
26 (3.6)
18 (2.5)
0.28
0.49 (0.24- 0.96)‡ 0.03
Liver dysfunction during first 7 days in pediatric ICU¶
Highest plasma level of total bilirubin - mg/dl
1.5±0.1
1.7±0.1
0.003
Highest plasma level of alkaline phosphatase- IU/liter
171±3
171±5
0.04
Highest plasma level of γ-glutamyltransferase - IU/liter
58±6
45±3
0.001
Highest plasma level of alanine aminotransferase -
72±8
113±20
0.64
IU/liter
Highest plasma level of aspartate aminotransferase -
179±26
262±48
0.76
IU/liter
Highest plasma level of C-reactive protein during first 7
79±4
90±4
0.007
days in pediatric ICU, as measure of inflammation – mg/liter
Duration of hospital stay - days
Index hospital
21.3±1.3
17.2±1.0
0.005 1.19 (1.07-1.33)
0.001
Index and transfer hospital
22.6±1.3
18.6±1.0
0.01
1.21 (1.08-1.34)
< 0.001
* Plus–minus values are means ±SE. No censoring was applied for the unadjusted comparisons of outcomes regarding duration of care. Data for all adjusted
outcomes for duration of care were censored at 90 days, and data for nonsurvivors were censored at 91 days.To convert the values for total bilirubin tomicromoles
per liter, multiply by 17.1.
† Odds ratios and hazard ratios were adjusted for the following risk factors: treatment center, age group, diagnosis group, PELOD score within the first 24 hours
after admission, and STRONGkids category.
‡ These values are adjusted odds ratios. All other values in this column are hazard ratios.
§ The duration of stay in the pediatric ICU was defined as the time from admission until the patient was ready for discharge. A patient was considered to be ready
for discharge as soon as all clinical conditions for discharge were fulfilled (i.e., the patient no longer required or was no longer at risk for requiring vital-organ
support).
¶ Total bilirubin levels were available for 1256 patients, alkaline phosphatase levels for 1234 patients, γ-glutamyltransferase levels for 1222 patients, alanine
aminotransferase levels for 1265 patients, aspartate aminotransferase levels for 1264 patients, and C-reactive protein levels for 1301 patients.